Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Thomas Martin, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA discusses the use of lenalidomide as a maintenance-based therapy, and the possibility to use it in conjunction with a proteasome inhibitor such as bortezomib in myeloma patients. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.